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Object. Prolactin-secreting pituitary adenomas may be managed by surgery, medication, radiotherapy, or observa­
tion. The authors reviewed a consecutive series of patients who were followed for at least 5 years after surgery to assess 
the prognostic significance of preoperative factors (tumor size and prolactin level) and an immediate postoperative fac­
tor (prolactin level obtained the morning after surgery) on long-term hormonal outcome, thereby clarifying the indi­
cations for surgical removal of tumor, the definition of successful treatment outcomes, and the nature of “recurrent” 
tumors.
Methods. Between 1979 and 1991, 241 patients with prolactinomas underwent transsphenoidal resection. Nineteen 
patients were lost to follow-up review, whereas the remaining 222 patients underwent measurement of their prolactin 
levels on postoperative Day 1 (POD 1), at 6 and 12 weeks, and every 6 months thereafter for a minimum of 5 years. 
On POD 1, prolactin levels in 133 patients (Group 1) were lower than 10 ng/ml, in 43 patients (Group 2) between 10 
and 20 ng/ml, and in 46 patients (Group 3) higher than 20 ng/ml. At 6 and 12 weeks, normal prolactin levels ( 20 
ng/ml) were measured in 132 (99%) of the 133 patients in Group 1 but only in 32 (74%) of the 43 patients in Group
2. By 5 years postoperatively, normal levels of prolactin were still measured in 130 patients (98%) in Group 1 com­
pared with only five patients (12%) in Group 2. No patient with a prolactin level lower than 3 ng/ml on POD 1 was 
found to have an elevated hormone level at 5 years. The likelihood of a long-term chemical cure was greater for pa­
tients with microadenomas (91% cure rate) than for those with macroadenomas (33%). Preoperative prolactin levels 
also correlated with hormonal outcome.
Conclusions. Prolactin levels lower than 10 ng/ml on POD 1 predict a long-term chemical cure in patients with mi­
croadenomas (100% cure rate) and those with macroadenomas (93% cure rate). In contrast, a cure is not likely to be 
obtained in patients with normal levels ranging between 10 and 20 ng/ml on POD 1 if they harbor macroadenomas 
(0% cure rate). A recurrence reported several years after surgery probably represents the presence of persistent tumor 
that was not originally removed. If the initial operation was performed by an experienced surgeon, however, reopera­
tion is not likely to yield a chemical cure.
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P ROLACTIN-secreting adenomas (prolactinomas) are the most common type of functional pituitary tu­mor. Despite their frequency, many aspects of their 
management remain controversial, including indications for 
operative removal, the definition of successful treatment 
outcomes, and therapy of recurrent tumors.3 These uncer­
tainties arise from several features that are unique to the 
biology and growth of these tumors. 1) Prolactinomas pro­
duce demonstrable symptoms relatively early in their devel­
opment and are often detected at smaller stages than other 
types of pituitary tumors, particularly in female patients.63
2) Despite the high prevalence of these tumors, the clin­
ical manifestations of hyperprolactinemia are not as life- 
threatening as those of excessive adrenocorticotrophic hor­
mone or growth hormone secretion in Cushing disease and 
acromegaly, respectively.21,22,32,59,63 Nonetheless, the endo­
crinological consequences of excessive prolactin secretion
Abbreviation used in this study: POD 1 = postoperative Day 1.
(such as hypogonadism, infertility, and osteoporosis) re­
quire treatment, preferably by addressing the underlying 
cause. 3) The natural history of prolactinomas often is in­
dolent, and neither tumor size nor prolactin levels change 
significantly over time in most cases. Data from six se­
ries of patients with microadenomas who refused treatment, 
including two of our own studies, indicate that the risk of 
progression to macroademona is less than 7% over a 2- to
6-year interval of observation.29,32,42,50,61 4) Unlike other
types of pituitary tumors, many prolactinomas may be safe­
ly and effectively managed by a regimen of pharmacologi­
cal agents alone. The efficacy of bromocriptine in reducing 
serum prolactin levels, diminishing tumor size, and inhibit­
ing tumor growth, is well established.7,35,47,58,60,65 The recent 
availability of cabergoline, a synthetic agonist with a high 
specificity and affinity for the D2 dopaminergic receptor, 
represents an advance over bromocriptine in its efficacy, 
tolerability, and compliance.6,11,1433,3957 
In an effort to resolve some of the disease management
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Fig. 1. Bar graph demonstrating stratification of 222 patients 
according to fasting prolactin levels on the morning after surgery. 
Group 1 consisted of 133 patients (60%) with serum prolactin lev­
els lower than 10 ng/ml, Group 2 included 43 patients (19%) with 
levels between 10 and 20 ng/ml, which is still considered normal, 
and Group 3 was composed of the remaining 46 patients (21%) in 
whom prolactin levels were greater than 20 ng/ml on POD 1.
controversies surrounding prolactinomas, we retrospective­
ly reviewed our experience with patients harboring these 
tumors whose cases were followed at least 5 years postop­
eratively to assess the prognostic value of serum prolactin 
levels obtained the morning after surgery. The ability to pre­
dict long-term outcomes in patients with prolactin-secreting 
pituitary adenomas immediately following transsphenoid­
al resection is important for determining the vigilance with 
which residual or recurrent tumor is sought and for allaying 
the concerns of patients who want to know whether their 
disease has been cured.19 Furthermore, this analysis of im­
mediate and long-term endocrinological response helps to 
clarify the issues of patient selection (indications for sur­
gery), the definition of successful treatment outcomes, and 
the nature of “recurrent” tumors.
Clinical Material and Methods
Since 1968, the senior surgeon (M.H.W.) has performed 
more than 2500 transsphenoidal operations, including more 
than 500 resections of prolactin-secreting pituitary adeno­
mas. From this latter group, we retrospectively selected a 
series of consecutive patients whose cases were followed 
for a minimum of 5 years after the procedure so that we 
could correlate their long-term outcomes with two preoper­
ative factors (tumor size and prolactin level) and hormone
levels determined in the immediate postoperative period. 
This study met the requirements of the institutional Review 
Board of the University of Southern California.
Patient Population
Between July 1979 and May 1991, 241 patients un­
derwent transsphenoidal surgery for prolactin-secreting tu­
mors. Nineteen of these patients were lost to follow-up 
review, whereas the remaining 222 patients have been ob­
served for a mean of 14 years (range 6-18 years).
There were 191 female and 31 male patients in this 
group, ranging in age from 15 to 63 years (mean 29 years). 
Although prolactinomas are discovered at autopsy with 
equal frequency in women and men, the gender differential 
in our study reflects disparities in the way such tumors are 
detected in vivo and referred for surgical evaluation. The 
demographic characteristics of this population are qualita­
tively similar to those from other large series of prolactin- 
secreting tumors.3,63
Clinical presentations of the disease in all patients includ­
ed primary amenorrhea in 12 female patients (5%), none of 
whom had associated galactorrhea. Secondary amenorrhea 
developed in an additional 160 female patients (72%), 82 
of whom were found to suffer from galactorrhea as well. 
Seventeen male patients (8%) presented with decreased li­
bido, impotence, or sterility; galactorrhea accompanied the 
symptoms in six of these patients. Visual loss, ranging in 
duration from 2 to 24 months, was the initial complaint in 
another 19 female patients (9%) and 14 male patients (6%).
The patients were almost equally divided between those 
harboring microadenomas (107 patients) and those with 
macroadenomas (115 patients). Preoperative prolactin lev­
els ranged from 89 to 6460 ng/ml and were distributed as 
follows: less than 200 ng/ml in 110 patients; 201 to 600 ng/ 
ml in 80 patients; and greater than 601 ng/ml in 32 patients 
(normal 20 ng/ml). in no patient was there a concomitant 
elevation of serum levels of growth hormone or insulin-like 
growth factor 1, and no tumor reacted positively for growth 
hormone with immunostaining.
Perioperative Management
Although most patients underwent initial attempts at 
pharmacological management with bromocriptine, surgery 
was mandated by bromocriptine failure or intolerance, pro­
gressive visual loss, or the desire for fertility. All patients 
were treated before the availability of cabergoline, which 
was approved for use by the United States Food and Drug 
Administration in 1997.
All patients underwent transsphenoidal microsurgical 
adenomectomy via a unilateral, transseptal approach.12 
Pathological confirmation of prolactinoma was obtained in 
all cases. The surgical objectives were gross-total tumor re­
section with preservation of normal gland, although in cases 
in which there was extensive invasion of the cavernous si­
nus, complete tumor removal was not always feasible. Hy- 
pophysectomy was not performed in any case. Dehydrated 
alcohol was applied to the tumor bed if the integrity of the 
arachnoid was maintained. Patients were not maintained on 
a regimen of glucocorticoids during the postoperative peri­
od unless they suffered from adrenal insufficiency preoper- 
atively.
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Postoperative Evaluation and Patterns o f 
Clinical Response
In all patients fasting morning prolactin levels were de­
termined by withdrawing serum on POD 1 and random 
serum levels were again sampled at 6 weeks, 12 weeks, 
and every 6 months thereafter for a minimum of 5 years. 
Based on these serial evaluations, three patterns of response 
could be observed. Some patients experienced immedi­
ate hormonal normalization that was maintained over time 
(“chemical cures”). Others experienced immediate normal­
ization, followed by a relapse of hyperprolactinemia after 
a variable period of time (“endocrinological recurrences”). 
The remaining demonstrated improved, but persistently ele­
vated levels of prolactin, even in the initial postoperative 
period (“immediate endocrinological failures”).
All patients who experienced endocrinological recur­
rence or immediate endocrinological failure underwent at 
least one follow-up imaging study after the elevated pro­
lactin level was detected.
Results
Endocrinological Response on POD 1
The 222 patients were stratified into three groups ac­
cording to their fasting prolactin levels on the morning 
after surgery (Fig. 1). Group 1 consisted of 133 patients 
(60%) in whom serum prolactin levels were lower than 10 
ng/ml. Group 2 included 43 patients (19%) in whom prolac­
tin levels were between 10 and 20 ng/ml, which are still 
considered normal values in our laboratory. Group 3 was 
composed of the remaining 46 patients (21%) in whom pro­
lactin levels were higher than 20 ng/ml on POD 1. The 
long-term outcomes of these three groups will be consid­
ered separately.
Long-Term Outcomes in Groups 1 and 2
Of the 222 patients in this study, 176 (79%) were as­
signed to Group 1 or 2 because hormone testing revealed 
normal prolactin levels on POD 1. All these patients im­
proved clinically. Galactorrhea resolved in all patients who 
suffered from this symptom preoperatively, and 151 (88%) 
of the 172 women presenting with amenorrhea resumed 
normal menses. In addition, 72 (75%) of 96 women who 
wanted to achieve pregnancy did so.
At 6 and 12 weeks postoperatively, normal prolactin lev­
els were maintained in 132 (99%) of the 133 patients in 
Group 1 and, and, by 5 years, prolactin levels were still 20 
ng/ml or lower in 130 patients (98%) (Fig. 2). No patient in 
whom the prolactin level was lower than 3 ng/ml on POD 
1 was found to have an elevated level after 5 years.
In contrast, normal prolactin levels were found in only 32 
(74%) of the 43 patients in Group 2 at 6 and 12 weeks, and 
after 5 years, in only five patients (12%) was a chemical 
cure maintained (Fig. 2).
Among the 176 patients in whom normal prolactin levels 
were measured on POD 1, 41 (23%) experienced endo­
crinological recurrence; three of these patients were from 
Group 1 and 38 were from Group 2. Two of the recurrences 
developed in women after successful gestations; both were 
Group 2 patients who resumed normal menses and became 
pregnant within 6 months after the operation.
Fig. 2. Bar graph showing long-term endocrinological respons­
es in patients in Groups 1 (gray bars) and 2 (black bars).
All patients who experienced relapse had harbored mac­
roadenomas preoperatively, whereas none of the patients 
with microadenomas suffered recurrence. The mean dura­
tion to relapse was 9 months postoperatively, and all recur­
rences developed within 33 months after surgery. No pa­
tient in whom a normal prolactin level was measured at 5 
years experienced a relapse subsequently.
All patients who experienced a relapse underwent at least 
one follow-up magnetic resonance imaging study, but only 
two were found to have imaging evidence of residual or re­
current tumor. One of these patients underwent reoperation, 
but failed to achieve a chemical cure for the disease even 
after the second procedure. In no instance did a recurrence 
manifest in a prolactin level exceeding 55 ng/ml. All 41 pa­
tients resumed treatment with bromocriptine, although in 
no case has a normal serum prolactin level been achieved. 
No patient has received postoperative radiotherapy or other 
adjuvant therapies.
Long-Term Outcome in Group 3
Among the 46 patients in whom immediate endocrino­
logical failure occurred, the mean prolactin level on POD 1 
was 780 ng/ml (range 33-2480 ng/ml). Most of these pa­
tients who had presented with amenorrhea and galactorrhea 
remained symptomatic, but 81% of those with visual im­
pairment improved. Two patients underwent reoperation, 
but a chemical cure was not achieved, despite the second 
procedure. All patients were treated with bromocriptine,
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TABLE 1
Effect o f  tumor size in long-term endocrinological outcome in 
222 patients who underwent surgery fo r  prolactinomas
Fig. 3. Bar graph demonstrating the effect of tumor size on im­
mediate postoperative endocrinological outcomes. Most of the 107 
patients with microadenomas were in Group 1 (gray bars), where­
as the distribution across groups in the 115 patients with macroade­
nomas (black bars) was nearly uniform.
but in no cases has a normal serum prolactin level been 
achieved. No patient has required postoperative radiation 
therapy.
Relationship Between Tumor Size and Outcome
Tumor size was found to correlate with both immediate 
(Fig. 3) and long-term (Table 1) endocrinological out­
comes. Among the 107 patients with microadenomas, nor­
mal prolactin levels were measured on POD 1 in 97 (91%), 
92 patients in Group 1 and five patients in Group 2. At five 
years postoperatively, a chemical cure was maintained in all 
97 patients (100%), and no patients with a microadenoma 
has experienced endocrinological recurrence.
In contrast, of the 115 patients with macroadenomas, the 
distribution among the three groups on POD 1 was more 
uniform: 41 patients were from Group 1, 38 from Group 2, 
and 36 from Group 3. Thus, normal prolactin levels were 
found immediately after surgery in only 79 patients (69%) 
with macroadenomas, and immediate endocrinological fail­
ure was observed in 36 patients (31%). At 5 years, only 38 
(48%) of these 79 patients in whom normal prolactin levels 
were measured postoperatively continued to benefit from a 
chemical cure, whereas the other 41 patients (52%) experi­
enced recurrence. These 38 patients all belonged to Group
1. Therefore, 38 (93%) of the 41 patients with macroadeno­
mas in Group 1 experienced chemical cures, whereas none
Group
5-Yr Cure Rate (%)
Patients W/ Microadenoma Patients W/ Macroadenoma
1 92 of 92 (100) 38 of 41 (93)
2 5 of 5 (100) 0 of 38 (0)
3 0 of 10 (0) 0 of 36 (0)
all patients 97 of 107 (91) 38 of 115 (33)
of the 38 patients in Group 2 achieved a cure (100% recur­
rence rate).
Relationship Between Preoperative Prolactin Level 
and Outcome
The preoperative prolactin level also correlated with en­
docrinological outcome (Fig. 4). Among the 110 patients 
presenting with levels lower than 200 ng/ml, chemical cure 
was achieved in 95 (86%) at 5 years. Of the 80 patients in 
whom values of prolactin were between 201 and 600 ng/ 
ml, a normal prolactin hormone level was maintained in 36 
(45%) at 5 years, whereas after more than 5 years a chemi­
cal cure was maintained in only four (12.5%) of 32 patients 
with preoperative levels greater than 601 ng/ml. The high­
est preoperative prolactin level that resulted in long-term 
endocrinological control was 920 ng/ml.
Discussion
Treatment goals for patients with prolactinomas include 
the following: 1) reduction of the tumor mass; 2) correction 
of the hyperprolactinemic state; 3) restoration of visual or 
cranial nerve function; and 4) preservation of anterior pitu­
itary function.3 Microsurgical resection and pharmacothera­
py are accepted means of accomplishing these objectives. 
Recently, gamma knife surgery also has been proposed as a 
primary treatment modality for prolactinomas.37 Our anal­
ysis of the immediate and long-term endocrinological re­
sponse after transsphenoidal adenomectomy has many im­
plications for the manner in which these therapeutic goals 
are achieved. Specifically, it helps clarify the issues of 
patient selection for surgery, the definition of successful 
treatment outcomes, and the nature of recurrent tumors.
Role of Transsphenoidal Surgery
in general, a rough correlation exists between the size of 
the tumor determined by imaging and pathological studies 
and the serum prolactin level, except in cases in which lo­
cal tumor invasion into adjacent venous sinuses produces a 
marked increase in serum prolactin that is out of proportion 
to tumor size.19,32,63 The preoperative prolactin level is help­
ful in formulating management strategies, because the abil­
ity to extirpate the tumor successfully and achieve a chem­
ical cure is reduced in cases of large or invasive lesions,4,41,48, 
54,56 as our study has confirmed (Fig. 4).
Central limitations of bromocriptine therapy include the 
side effects of the medication, the requirement for lifelong 
administration, and the uncertainty of its safety during preg­
nancy. Approximately 20 to 30% of patients complain of
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one or more adverse drug effects, including nausea, vom­
iting, constipation, postural hypotension, psychosis, and 
depression, and approximately 5 to 10% find that bro­
mocriptine treatment is so intolerable that they therefore re­
quest surgery.3303744 In most cases, the medication must be 
continued indefinitely, because cessation usually results in 
the return of symptomatic hyperprolactinemia and reexpan­
sion of the tumor.30,47,54 In addition, the United States Food 
and Drug Administration recommends discontinuing bro­
mocriptine once pregnancy has been established, because 
of concerns about its safety for both mother and fetus.1 The 
volume of the normal pituitary gland increases by approxi­
mately 70% during pregnancy,24 however, and up to 35% of 
pregnant patients experience symptomatic enlargement of 
their tumor.24 3158 The superimposition of these two effects 
can lead to compression of optic structures during gestation 
if bromocriptine treatment is suspended. The teratogenic 
potential of cabergoline has not been extensively investi­
gated and consequently, this drug is generally not consid­
ered to be a first-line therapy for the treatment of infertility 
associated with hyperprolactinemia.31,39 Thus, the desire for 
pregnancy, particularly in patients harboring a macroadeno­
ma, constitutes a relative indication for surgical resection.64 
In our series, 72 of the 96 women who wished to become 
pregnant did so after transsphenoidal adenomectomy.
Up to 40% of tumors fail to shrink in response to bromo­
criptine therapy.183847 Furthermore, there are rare cases in 
which patients initially respond to bromocriptine with a re­
duction in tumor size and normalization of serum prolactin, 
and subsequently experience recrudescence of the tumor 
even as medical therapy continues.5,7,47 The tumor may un­
dergo a process of dedifferentiation and become refracto­
ry to further dopamine agonist action, as evidenced by the 
in vitro resistance of cultured lactotrophs to high concen­
trations of bromocriptine.8,38 Similarly, a discrepancy in the 
clinical response, as judged by tumor size and circulating 
prolactin levels, may develop. Despite a marked reduction 
in serum prolactin levels throughout the duration of bromo­
criptine therapy, for instance, some patients may experi­
ence continued tumor expansion and progressive symptoms 
from mass effect.13,23,63 Conversely, others may suffer the 
adverse effects of persistent hyperprolactinemia, despite se­
rial imaging studies that indicate continued regression in tu­
mor size.2 Bromocriptine resistance or dissociation between 
tumor growth and serum prolactin measurements constitute 
other indications for surgical resection.
Although it is intuitive to suggest that pretreatment with 
bromocriptine will shrink the tumor and facilitate sur­
gical resection, there have been no conclusive reports of 
higher cure rates after such preoperative measures.15,20 In 
fact, some surgeons believe that preoperative bromocriptine 
therapy produces adverse effects on the consistency of the 
adenoma, impeding tumor resection,17,25,56,63 although that 
has not been our experience.62 Bromocriptine might also in­
crease the radioresistance of prolactinomas to gamma knife 
surgery.26
Our study confirms that transsphenoidal resection is a 
highly effective modality in the management of prolac­
tin-secreting pituitary tumors among patients who are not 
considered candidates for medical therapy for the reasons 
outlined above. For microadenomas, the likelihood of long­
term chemical cure exceeds 90% (Table 1). In patients with 
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Fig. 4. Bar graph demonstrating the effect of preoperative pro­
lactin level on long-term outcome. The 5-year cure rates were 86% 
for patients with preoperative prolactin levels lower than 200 ng/ 
ml; 45% for patients with preoperative levels between 201 and 600 
ng/ml; and 12.5% in patients with preoperative levels greater than 
601 ng/ml.
associated morbidity rate was low. These results compare 
favorably with those of pharmacological management. In 
addition, the economic costs of surgical resection may be 
comparable with those of lifelong medical therapy.49 The 
experience of other centers corroborates this high rate of 
surgical success among cases of microprolactinomas.17-19,28, 
30,32,36,51,54-56,63 Thus, strong consideration should be given to 
surgical intervention in patients harboring smaller tumors 
without significant hyperprolactinemia.
In cases of larger tumors, however, surgical cures are 
much less common.17,18,28,30,32,36,51,54,55,63 Using the classifica­
tion scheme proposed by Hardy, the cure rates of Stage I, II,
III, and IV tumors after transsphenoidal resection are 84, 
50, 25, and 0%, respectively.34 Tumors associated with pre­
operative prolactin levels greater than 200 ng/ml recur in 
more than 50% of cases after surgery alone, and the rate of 
recurrence of hyperprolactinemia after surgery for macro­
adenomas in patients with prolactin levels greater than 250 
ng/ml exceeds 70%.22 In the current series, only 38 (33%) 
of 115 patients with tumors larger than 1 cm achieved 
chemical cures, as opposed to 91% of those with tumors 
smaller than 1 cm (Table 1). Therefore, bromocriptine may 
be considered as the initial therapy for patients in whom 
surgical resection is deemed unlikely to result in a chemical 
cure.27,53,65 For patients in whom surgery has failed, subse­
quent treatment with reduced doses of bromocriptine is of­
ten better tolerated and more effective than this treatment 
before surgery.34,36,41 As our study has shown, reoperation is 
seldom necessary, and postoperative radiotherapy is usual­
ly not required.
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Predictive Value o f Immediate Postoperative 
Prolactin Levels
Patients should undergo a systematic routine assessment 
of endocrinological outcome postoperatively. Our study 
demonstrates that serum prolactin levels obtained the morn­
ing after surgery predict long-term results. Levels lower 
than 10 ng/ml on POD 1 predict cure (Table 1) in patients 
with microadenomas (100%) as well as in those with mac­
roadenomas (93%). No patient in our study in whom the 
prolactin level was lower than 3 ng/ml on POD 1 was found 
to have an elevated level at 5 years postoperatively.
In contrast, patients with normal levels between 10 and 
20 ng/ml on POD 1 remain at risk for endocrinological re­
currence if the preoperative tumor size exceeds 10 mm (Ta­
ble 1). All Group 2 patients with macroadenomas expe­
rienced recurrence by 5 years, whereas none of those with 
microadenomas suffered relapse. These data indicate that 
the traditional criteria used to determine successful adeno­
ma resection in the immediate postoperative period (prolac­
tin levels 20 ng/ml) may be too liberal.
In his early experience, Wilson63 also found that imme­
diate postoperative prolactin levels have prognostic value. 
Levels lower than 5 ng/ml virtually assured cure, whereas 
those greater than 15 ng/ml implied existence of residual tu­
mor and the probability of regrowth. In a later study, Wilson 
and coworkers16 found that the likelihood of cure was 84% 
for patients with postoperative levels lower than 5 ng/ml, 
but only 67% for those with levels higher than 20 ng/ml. 
Serri and Massoud and colleagues30,46 have also suggested 
that the risk of recurrence is increased among patients with 
early postoperative prolactin levels in the upper limit of the 
normal range. In their series, prolactin levels measured 7 to 
30 days after surgery were significantly lower in patients in 
whom normoprolactinemia was maintained long term (6.4 
ng/ml) than in those who experienced relapse (11.7 ng/ 
ml).46 In the study by Schlechte and colleagues,43 the mean 
serum prolactin level 6 weeks after surgery in patients in 
whom the disease was cured (7 ng/ml) was less than that in 
patients who later experienced recurrence (13 ng/ml), al­
though this difference was not statistically significant. Post­
operative prolactin levels near the upper limit of normal 
were also found to be prognostic of hyperprolactinemia re­
currence in the study by Charpentier, et al.10
Nature o f Endocrinological Recurrence
After surgery, postoperative measurements of prolactin 
levels are the most sensitive indices of the completeness 
of resection and the possibility of recurrence. As we have 
shown, the finding of a normal prolactin level of 10 to 20 
ng/ml on POD 1 indicates the possibility that residual tumor 
remains. Thus, the results of our analysis of immediate and 
long-term endocrinological responses after transsphenoid­
al adenomectomy suggest that recurrences reported after 
several years most likely represent persistent tumor that was 
not originally removed.
In other series, relapse of hyperprolactinemia after initial 
hormonal normalization occurred frequently. Recurrence 
rates range from 17 to 50% for microadenomas and from 20 
to 80% for macroadenomas, depending on the duration of 
follow-up review, experience of the surgeon, and other fac­
tors.917-19,28,30,4043-46,51,52,56 Differences in surgical technique 
may also underlie the variation in reported rates of relapse
after apparently successful adenomectomy. For instance, 
based on the hypothesis that delayed recurrences in situ re­
sult from residual tumor cells at the periphery of an ade­
noma, some have proposed performing an enlarged rather 
than selective adenomectomy by removing a layer of nor­
mal pituitary gland at the outer edge of the tumor and the 
pituitary capsule in contact with the sellar meninges.18,56 Us­
ing this technique in 26 patients with tumors smaller than 
20 mm in diameter and prolactin levels lower than 200 ng/ 
ml, Grisoli and associates18 obtained normal prolactin lev­
els in all cases after an average of 16 months. This length 
of follow-up review is short, however, and it remains to 
be proven whether this technique results in a lower inci­
dence of delayed recurrence. In our series, chemical cure 
was achieved in 86% of the 110 patients presenting with 
prolactin levels lower than 200 ng/ml at 5 years (Fig. 4).
Relapses usually occur within the first few years after 
surgery, although they have been reported more than 10 
years later.30,51,52 Often, such recurrences are asymptomat- 
ic,28 30434546 but even in patients without overt clinical mani­
festations, treatment is indicated to prevent osteoporosis 
and other endocrinological sequelae of hyperprolactinemia.
In most cases of relapse or immediate endocrinological 
failure, imaging of the sella turcica fails to reveal residual or 
recurrent adenoma.28,30,43,45,46,52 Our study indicates that, if the 
original operation was performed by an experienced sur­
geon, reoperation is not likely to yield a chemical cure. This 
observation may reflect the fact that by following vigilant 
protocols for sampling postoperative prolactin levels, most 
tumor recurrences will be detected early. In our series, no 
recurrence produced a serum level greater than 55 ng/ml. 
Alternatively, this observation may imply that there are rea­
sons for recurrent hyperprolactinemia other than regrowth 
of residual tumor remnants. These include a secondary 
empty sella, primary hypothyroidism, or a persistently dis­
ordered hypothalamic-pituitary axis characterized by re­
duced delivery of prolactin-inhibiting factors after surgery 
due to scarring at the tumor cavity.28,30,46,52 The dynamic 
responses of lactotrophs to provocative stimuli such as thy- 
rotrophin-releasing hormone or metoclopramide may help 
distinguish between these possibilities.18,19,28,43,53,56
Recently, Thomson and colleagues52 analyzed outcomes 
of patients with recurrent hyperprolactinemia after initial 
hormonal normalization. Relapses occurred 2 to 10 years 
postoperatively in eight (18.2%) of 44 patients undergoing 
transsphenoidal removal of a microprolactinomas; howev­
er, the relapse was permanent in only two of these patients. 
Of the remaining six patients, four experienced sponta­
neous remission after 6 to 7 years of recurrence and only 
marginally elevated prolactin levels were measured in two 
others. The authors concluded that recurrence of hyperpro­
lactinemia after transsphenoidal surgery is not necessarily a 
permanent feature and does not inevitably indicate opera­
tive failure.
Conclusions
Prolactin levels lower than 10 ng/ml on POD 1 predict 
long-term chemical cure in patients with microadenomas 
(100%) as well as in those with macroadenomas (93%). 
In contrast, a cure is not likely to be obtained in patients 
with normal levels of prolactin between 10 and 20 ng/ml on
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POD 1 if these patients harbor macroadenomas (0% cure 
rate). Recurrences reported several years after surgery prob­
ably represent persistent tumor that was not originally re­
moved. if  the initial operation was performed by an experi­
enced surgeon, however, reoperation is not likely to yield a 
chemical cure.
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